13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.
The press-release you may find here
Press conference: Announcement about the start of Pfizer and NovaMedica a long-term strategic partnership
Photo from right to left: Leonid Melamed, Head of Managing Company RMI Partners, Member of the Boards of Directors of NovaMedica, Brian Dovey, Partner at Domain Associates, Member of the Board of Directors of NovaMedica, Anatoly Chubais, Chairman of the Executive Board of RUSNANO, Chairman of the Board of Directors of NovaMedica, Petra Danielsohn-Weil, Regional President of Europe, Pfizer Essential Health Business, Andrey Trapesnikov, Deputy Chairman of the Executive Board of RUSNANO.
Photo: Petra Danielsohn-Weil, Regional President of Europe, Pfizer Essential Health Business, Anatoly Chubais, Chairman of the Executive Board of RUSNANO, Chairman of the Board of Directors of NovaMedica.
Photo: Anatoly Chubais, Chairman of the Executive Board of RUSNANO, Chairman of the Board of Directors of NovaMedica, Brian Dovey, Partner at Domain Associates, Member of the Board of Directors of NovaMedica.
Photo: Brian Dovey, Partner at Domain Associates, Member of the Board of Directors of NovaMedica.
Photo: Leonid Melamed, Head of Managing Company RMI Partners, Member of the Boards of Directors of NovaMedica
Photo: Press conference Announcement about the start of Pfizer and NovaMedica a long-term strategic partnership
All photos made by RUSNANO Press Center.
More picrures:
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024